Protagenic Therapeutics, Inc.\new Marketable Securities (Current)
Protagenic Therapeutics, Inc.\new (PTIX) had Marketable Securities (Current) of $1.59 million as of 2024-03-31, per its 10-Q filed 2024-05-15.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2025-03-31
- 2024-03-31: Marketable Securities, Current $1.59M.
- 2023-12-31: Marketable Securities, Current $2.77M.
- 2023-09-30: Marketable Securities, Current $5.12M.
- 2023-06-30: Marketable Securities, Current $5.82M.
| Period end | Marketable Securities, Current |
|---|---|
| 2024-03-31 | $1.59M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $2.77M 10-K · filed 2025-03-31 |
| 2023-09-30 | $5.12M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $5.82M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $7.51M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $7.76M 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $7.99M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $8.53M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $9.30M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $9.83M 10-K · filed 2023-03-31 |
| 2021-09-30 | $10.39M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |